Physiologically-based pharmacokinetic scaling in retinoid developmental toxicity
msra(2000)
摘要
Requirement of the retinoids (as the retinoic acid precursors retinol and its esters) in normal embryonic development was
first demonstrated in farm and laboratory animals more than 60 years ago. While there are scattered reports of anophthalmia
and other terata among offspring of malnourished women [1], the requirement for adequate dietary retinol and retinyl esters in prenatal and neonatal development has been documented
most clearly from intervention trials [2-4]. Bolus administration of 200 000 IU vitamin A once per month during the first four months of life in deficient populations
reduced neonatal mortality 30-60% [5]. Among low birth weight infants, low hepatic and circulating retinol levels have been demonstrated [6-8]; it is evident that maternal retinoid deficiency (plasma retinoid ~10-20 μg/100 ml) increases risk of embryonic and fetal
demise and precipitates retarded intrauterine growth. One factor contributing to increased mortality among neonates born to
retinoid-deficient mothers is reduced development of the fetal lung [9,10]. The present U.S. National Research Council recommended daily allowance (RDA) of dietary retinoid for adults is 50001U and
it is increased for pregnant/lactating women to 8000 IU (2400 retinol equivalents). The RDA values are based upon maintenance
of normal dark adaptation, taking into account bioavailability and individual differences in vitamin utilization. The RDA
assumes 50% of total daily intake as retinol and its esters and 50% from β-carotene.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要